Aclarion Adds First Private Practice Site to CLARITY Trial, Accelerating Enrollment for Chronic Low Back Pain Study

Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify chronic low back pain sources, announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY (Chronic Low back pain Randomized Independent Trial studY) trial. Based in Beverly Hills, this private practice is known for complex spinal procedures and early adoption of innovative technologies, marking the first private practice site in the trial.

The inclusion of a premier private practice reflects growing interest in integrating Nociscan into real-world clinical workflows beyond academic centers. Dr. Todd Lanman, a neurosurgeon with over 25 years of experience and founder of Lanman Spinal Neurosurgery, stated, ‘Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making by more precisely identifying pain-generating discs.’

The CLARITY trial is a prospective, randomized, multi-center study enrolling 300 patients undergoing surgical treatment (fusion or total disc replacement) for discogenic low back pain. The primary endpoint is change in back pain on a 100mm VAS at 12 months compared to baseline, with several secondary endpoints. Aclarion anticipates an initial internal data readout and early interim results disclosure in Q4 2026.

Ryan Bond, Chief Strategy Officer of Aclarion, noted, ‘Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice.’ Dr. Lanman added, ‘Matching the right procedure to the right patient is what moves the field forward.’

Chronic low back pain affects approximately 266 million people worldwide. Aclarion’s Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful lumbar discs by quantifying chemical biomarkers associated with disc pain. When all Nociscan-positive discs are treated, the technology demonstrates a 97% surgical success rate.

More information about the CLARITY trial is available at CLARITY Trial. To find a Nociscan center, view the site map here.

This news story relied on content distributed by PRISM Mediawire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Aclarion Adds First Private Practice Site to CLARITY Trial, Accelerating Enrollment for Chronic Low Back Pain Study.

The post Aclarion Adds First Private Practice Site to CLARITY Trial, Accelerating Enrollment for Chronic Low Back Pain Study appeared first on citybuzz.